Cross-Sector entity
Paltusotine is most often covered alongside Crinetics Pharmaceuticals, which appears in 3 of these 4 stories. The 155-day window averages about 0.2 stories each week. The busiest single day carried 2. The clearest coverage concentration is acquisition: 1 of 4 stories, with the rest divided among 3 other categories.
4 verified stories tracked
Last mentioned: Jul 31, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Paltusotine is most often covered alongside Crinetics Pharmaceuticals, which appears in 3 of these 4 stories. The 155-day window averages about 0.2 stories each week. The busiest single day carried 2. The clearest coverage concentration is acquisition: 1 of 4 stories, with the rest divided among 3 other categories. This profile follows 4 Cross-Sector stories mentioning Paltusotine across the period from February 27, 2026 to July 31, 2026. Each carries 2.5 original sources on average.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Paltusotine. Shared-story counts are live from our verified record — not editorial picks.
Vertex announces $10 billion acquisition of Crinetics
Vertex Pharmaceuticals agrees to buy Crinetics Pharmaceuticals for $10 billion in cash, gaining a pipeline of endocrine therapies; the deal has not yet closed.
Vertex's $10B cash acquisition of Crinetics sets a powerful precedent, suggesting Viking Therapeutics could command a $15–20B price tag in a consolidating obesity market. For investors, VKTX's late-stage pipeline and the appetite of cash-rich pharma giants offer a high-risk, high-reward M&A setup.
Vertex's $10B buyout of Crinetics highlights the frenzied demand for metabolic pipelines. Viking Therapeutics, with a Phase 3 obesity asset and an oral candidate nearing late-stage trials, now looks like the most logical next takeover target in the rapidly expanding $190B weight-loss market.
Source: Prosper Junior Bakiny (us) · fool.com
Crinetics Pharmaceuticals (CRNX) reported Q4 2025 results, highlighting critical progress in its endocrine pipeline and preparations for the commercial launch of paltusotine. Alongside results from MDxHealth and Baldwin, the earnings cluster reflects a strategic transition for mid-cap healthcare and service firms navigating the 2026 market landscape.
The Q4 2025 earnings reports from Crinetics, MDxHealth, and Baldwin highlight a pivotal shift toward precision diagnostics and specialized endocrine therapies. These results underscore a robust recovery in diagnostic volumes and a maturing pipeline for rare disease treatments entering commercialization phases.
Source: seekingalpha.com · flipboard.com
